Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia
Sponsor: HK inno.N Corporation
Summary
The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.
Official title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-09
Completion Date
2028-02
Last Updated
2026-06-25
Healthy Volunteers
No
Conditions
Interventions
IN-207907 120 mg
IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
IN-207907 240 mg
IN-207907 240 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
IN-207907 360 mg
IN-207907 360 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
Placebo
Placebo will be administered by intravenous injection at 4-week intervals for a total of 3 doses.